Why Farbe Firma is the Leading Injectable Manufacturer in Tonga
Why Farbe Firma is the Leading Injectable Manufacturer in Tonga
Last Updated: 21 September 2026
TL;DR: Tonga has had a commenced medicines statute since 1 July 2010. The Therapeutic Goods Act runs a Registered List maintained by a national committee, and its Schedule names seven countries of manufacture: Australia, Canada, Fiji, Sweden, the United Kingdom, the United States and New Zealand. India is not among them. The same section also allows listing after assessment of a detailed submission, while a government customs guideline states the seven-country list is the only way in. Both are official Tongan documents and both are printed here.
Key Takeaways
The governing instrument is the Therapeutic Goods Act, Chapter 12.16 in the 2020 Revised Edition, in force since 1 July 2010 with regulations commenced the following year. This is not a dormant register: the 2021 amendment touched only one section and added a part on methamphetamine precursors, leaving the registration provisions and the Schedule untouched.
The Schedule to section 7 lists seven countries of manufacture and India is not one. The section reads as an alternative rather than a gate: a product qualifies if registered in a Schedule country, or if found to meet the requirements after assessment of a detailed submission and payment of the prescribed fee. A customs guideline nevertheless describes the list as exclusive. We report the conflict and do not resolve it.
There is no foreign-site layer. The Act's only reference to good manufacturing practice applies to premises in the Kingdom and confers no power to inspect an overseas factory. What it asks for instead is a certificate under the WHO scheme signed by the regulator of the manufacturing country, plus evidence the product is registered for sale there. The named pharmacopoeial standards are USP and BP; IP is not named.
The commercial gate is larger than the regulatory one. Tonga's health ministry plan states the country lacks the purchasing power to attract manufacturers and that use of a middleman raises prices, the customs guideline records that no pharmaceutical manufacturers or wholesalers operate in Tonga, and import licences may be applied for only by a pharmacist, veterinary practitioner, wholesaler or retailer.
Introduction: What an Injectable Manufacturer in Tonga Is Actually Being Asked For
Tonga is a market of a little over one hundred thousand people, and the temptation is to assume a country that small regulates medicines loosely or not at all. That assumption is wrong and would be expensive. The Therapeutic Goods Act has been in force since 1 July 2010, its regulations since the following year, and it establishes a Registered List, an application, a fee and a national committee whose decision the Act declares final.
The harder question is not whether Tonga regulates but which document governs. The Schedule names seven countries of manufacture and India is absent. Read alone, that looks like a closed door. Read in context, the section offers a second limb: assessment of a detailed submission on payment of the prescribed fee. A customs guideline from another arm of the same government says only medicines registered in those seven countries can join the list. Two official documents, two readings.
What Sets a World-Class Injectable Manufacturer in Tonga's Supply Chain Apart
Separate the layers before quoting anyone a pathway. At the site layer, Tonga asks nothing of a foreign factory directly: the Act's single reference to good manufacturing practice concerns premises in the Kingdom, and no overseas inspection power appears in it. At the product layer the test is documentary. The Act asks for a certificate issued under the WHO certification scheme and signed by the regulator of the country of manufacture, and that the product already be registered for sale in that same country.
At the importer layer the rule is strict and easily missed. An application for an import licence may be made only by a pharmacist, a veterinary practitioner, a wholesaler or a retailer. A foreign manufacturer cannot hold that licence, so a Tongan licensed partner is structurally necessary. Set against the customs guideline's statement that no pharmaceutical wholesalers are established in Tonga, this is the constraint that shapes every entry plan and should be solved before a dossier is compiled.
Quality Systems Behind Every Sterile Injectable Batch
Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Because Tonga names USP and BP and does not name IP, our specifications are written to the compendial standard the buyer needs rather than a house default. Batch release rests on HPLC and GC assay and impurity work, Karl Fischer, LAL endotoxin testing, sterility, particulate matter and container-closure integrity.
Stability work is matched to a hot, humid island destination rather than a temperate default, and runs to ICH Q1A with photostability under ICH Q1B where the molecule calls for it. Freight reality is designed in: long routes to the central Pacific consume shelf life, so remaining life at delivery is planned rather than hoped for, and cold-chain products ship in validated configurations with temperature records. Dossiers are assembled in CTD and ACTD format.
Why Farbe Firma is the Trusted Injectable Manufacturer in Tonga for Global Buyers
Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In a market whose statute turns on documents rather than factory inspections, what matters is that the documents are real, current and internally consistent. We supply a certificate under the WHO scheme from the Indian regulator, evidence of Indian registration for the same product, specifications written to USP or BP, and analytical data that matches the certificate.
We are equally direct about the limits of what any Indian manufacturer can claim here. India's CDSCO appears on the WHO Maturity Level 3 listing with a scope column reading vaccines, not medicines, and on the transitional register on the same terms, so a maturity-level argument does no work for a small-molecule injectable. Tonga's Act makes no reference to WHO maturity levels at all. Whether India already appears on the Registered List we could not check, because the ministry site was unavailable, and we will not guess either way.
The funding picture is narrower than it first looks. The Global Fund's 2026 eligibility list records Tonga as an upper-middle-income country nonetheless eligible for HIV and tuberculosis, under an exception for small island economies classified as IDA-eligible small states. Tonga has never been Gavi-eligible, and the verified regional vaccine channel is development-bank financed and procured through a United Nations agency. For non-vaccine medicines we found no pooled platform, so the ministry route remains the realistic path.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Tonga have a medicines register?
Yes. The Therapeutic Goods Act has been in force since 1 July 2010, with regulations commenced the following year, and it establishes a Registered List maintained by a national drugs and medical supplies committee. What the Act does not supply is a processing timeline, a validity or renewal period, or a prescribed dossier format, none of which we could locate; the Act also states that the committee's decision is final.
Can a medicine manufactured in India be listed in Tonga?
This is the question the sources disagree on, and we will not pretend otherwise. The Schedule names seven countries of manufacture and India is not among them, but the same section allows listing after assessment of a detailed submission on payment of the prescribed fee. A customs guideline states that only medicines registered in those seven countries can be included. Absence from a list is not a prohibition, and an alternative limb on paper is not a proven route. Ask the ministry in writing.
Does Tonga require a WHO-GMP certificate for the manufacturing site?
Not as such. The Act's only mention of good manufacturing practice concerns premises within the Kingdom and gives no power to inspect or license an overseas site. What it requires instead is a certificate issued under the WHO certification scheme by the regulator of the country of manufacture, plus evidence the product is registered for sale there. A WHO-GMP certificate and a WHO-scheme product certificate are different documents.
Who can hold an import licence in Tonga?
Only a pharmacist, a veterinary practitioner, a wholesaler or a retailer may apply, so a foreign manufacturer cannot import directly and a Tongan licensed partner is a statutory requirement. The customs guideline records that no pharmaceutical manufacturers or wholesalers are established in Tonga, which makes qualifying that partner the first practical step of any entry plan.
Is donor or pooled procurement funding available in Tonga?
Partly, and the shape matters. The Global Fund's 2026 eligibility list records Tonga as eligible for HIV and tuberculosis despite upper-middle-income status, through an exception covering small island economies classified as IDA-eligible small states. Tonga is listed among countries never eligible for Gavi support. The regional vaccine channel we could verify is development-bank financed and procured through a United Nations agency.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog
Comments